行情

INSM

INSM

Insmed
NASDAQ

实时行情|Nasdaq Last Sale

21.46
-1.23
-5.42%
盘后: 21.46 0 0.00% 16:07 01/17 EST
开盘
22.94
昨收
22.69
最高
23.02
最低
21.22
成交量
134.84万
成交额
--
52周最高
33.13
52周最低
15.33
市值
19.17亿
市盈率(TTM)
-5.9003
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

INSM 新闻

  • Insmed to Present at the 38th Annual J.P. Morgan Healthcare Conference
  • PR Newswire.01/09 13:00
  • Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • PR Newswire.01/03 21:05
  • Benzinga's Top Upgrades, Downgrades For January 2, 2020
  • Benzinga.01/02 15:43
  • Insmed Incorporated (NASDAQ:INSM): When Will It Breakeven?
  • Simply Wall St..01/01 19:24

更多

所属板块

生物技术和医学研究
-0.16%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

INSM 简况

Insmed Incorporated is a global biopharmaceutical company. The Company’s product ARIKAYCE (amikacin liposome inhalation suspension) is developed for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The Company's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that offers a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.
展开

Webull提供Insmed Incorporated的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。